~~<i id='B0C3E26384'><strike id='B0C3E26384'><tt id='B0C3E26384'><pre id='B0C3E26384'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

author：leisure time 2025-09-29 22:49:47 - browse：3

LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.

The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met.

AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： PEPFAR is under serious threat — and so is global health

hotspot

focus

explore

hotspot

Foodmakersdon'twantregulatorstofocusonultra-processedfoodswhentheygotoupdatedietaryguidelines.DanKit

WSS

New weight loss drugs vying to be the next Wegovy or Mounjaro

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Long Covid needs a new name — and a new frame

Change Healthcare cyberattack shows risk of industry consolidation

Food makers tried to stack nutrition panel with preferred experts

Acelyrin, a rare IPO success, stumbles in its first big test

knowledge

knowledge

hotspot

Continuity nursing helped my family in our darkest PICU moments

FDA proposes changes to key medical devices approval pathway

Walensky prepares to leave CDC — and Congress — behind

How to make the FDA’s new prescription one

Novavax promises a turnaround & Lilly roils the obesity market

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

Novavax promises a turnaround & Lilly roils the obesity market

Children’s Hospital revives plan for pedestrian bridge

ChatGPT in medicine: STAT answers readers' burning questions

IRA could hurt research into orphan drugs for rare diseases

focus

Food makers tried to stack nutrition panel with preferred experts

What to make of Biden’s latest efforts on cancer research

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

Walmart eyes Medicare Advantage provider ChenMed

CDC panel: People 65 and older should get a Covid spring booster shot

Acelyrin, a rare IPO success, stumbles in its first big test

explore

hotspot

hotspot

hotspot